Algert Global LLC Boosts Holdings in Penumbra, Inc. (NYSE:PEN)

Algert Global LLC raised its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 29.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,974 shares of the company's stock after purchasing an additional 4,362 shares during the quarter. Algert Global LLC's holdings in Penumbra were worth $4,506,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. UMB Bank n.a. grew its position in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after acquiring an additional 70 shares during the last quarter. Hurley Capital LLC purchased a new stake in Penumbra in the 4th quarter valued at about $56,000. Huntington National Bank grew its stake in Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after acquiring an additional 154 shares in the last quarter. Mather Group LLC. raised its stake in shares of Penumbra by 208.0% during the fourth quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after acquiring an additional 208 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its stake in Penumbra by 25.0% in the fourth quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after purchasing an additional 75 shares in the last quarter. Institutional investors own 88.88% of the company's stock.

Wall Street Analysts Forecast Growth

PEN has been the subject of several recent research reports. Stifel Nicolaus set a $318.00 price target on Penumbra and gave the stock a "buy" rating in a research report on Thursday, April 24th. Canaccord Genuity Group lifted their price objective on shares of Penumbra from $323.00 to $340.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Robert W. Baird raised their target price on shares of Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Truist Financial increased their price objective on Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a report on Thursday, April 24th. Finally, StockNews.com raised Penumbra from a "hold" rating to a "buy" rating in a research report on Thursday, April 24th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $302.40.

Insider Buying and Selling

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total value of $172,458.00. Following the transaction, the executive vice president now directly owns 66,539 shares of the company's stock, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Maggie Yuen sold 2,000 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $286.00, for a total transaction of $572,000.00. Following the completion of the transaction, the chief financial officer now directly owns 15,243 shares in the company, valued at $4,359,498. This trade represents a 11.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 159,096 shares of company stock valued at $44,959,983. Company insiders own 5.00% of the company's stock.

Penumbra Stock Performance

NYSE:PEN traded up $8.52 during mid-day trading on Friday, hitting $297.25. 972,988 shares of the company's stock traded hands, compared to its average volume of 426,873. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $277.75 and a two-hundred day moving average of $260.95. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The firm has a market capitalization of $11.51 billion, a price-to-earnings ratio of 874.26, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $324.14 million during the quarter, compared to analyst estimates of $315.72 million. During the same period last year, the company earned $0.41 earnings per share. The company's revenue was up 16.3% on a year-over-year basis. On average, equities analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.